ImmunoCellular Therapeutics’ ICT-107 featured on CNN’s Sanjay Gupta MD
LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics (IMUC) (NYSE MKT: IMUC) a clinical stage biotechnology company that is focused on developing new immune-based products to treat cancer, announced today that it was featured on CNNs Sanjay Gupta MD last weekend. The show profiled IMUCs dendritic cell-based vaccine, ICT-07, which is currently undergoing a Phase IIb clinical trial treating newly diagnosed patients with glioblastoma multiforme, an aggressive, terminal form of brain cancer.
Dr. Sanjay Gupta is the multiple Emmy®-award winning chief medical correspondent for CNN. Gupta, a practicing neurosurgeon, plays an integral role in CNNs reporting on health and medical news for Starting Point with Soledad O'Brien, Anderson Cooper 360°, CNN documentaries, and anchors the weekend medical affairs program Sanjay Gupta MD. Gupta also contributes to CNN.com and CNNHealth.com.
ImmunoCellulars Phase IIb trial of ICT-107 is a double-blind, placebo-controlled, 2:1 randomized study designed to evaluate the safety and efficacy of ICT-107. The study is enrolling patients at medical institutions in collaboration with leading experts and opinion leaders in neuro-oncology.
A transcript of the CNN show can be found at: http://edition.cnn.com/TRANSCRIPTS/1208/11/hcsg.01.html
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics (IMUC) is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company is currently conducting a Phase IIb trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma. To learn more about IMUC, please visit www.imuc.com.
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that the prior safety and efficacy results for ICT-107 will not be confirmed in current or any subsequent trials of that product candidate in statistically significant larger patient populations. Additional risks and uncertainties are described in IMUCs most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For ImmunoCellular Therapeutics, Ltd.
James Young, 212-732-4300
Source: ImmunoCellular TherapeuticsCopyright Business Wire 2012